Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. SUMMARY: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2.11 MMSE points at 6 months) as for patients with Alzheimer disease/vascular dementia (0.91 MMSE points at 6 months). Key Messages: AChEIs demonstrate a modest effect versus control on MMSE scores which is moderated by dementia subtype. For memantine the effect is smaller.

Original publication

DOI

10.1159/000486546

Type

Journal article

Journal

Dement Geriatr Cogn Disord

Publication Date

2018

Volume

45

Pages

131 - 151

Keywords

Acetylcholinesterase inhibitor, Alzheimer disease, Memantine, Meta-analysis, Systematic review, Vascular dementia, Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Dementia, Vascular, Dopamine Agents, Humans, Memantine, Treatment Outcome